JP2005534624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534624A5 JP2005534624A5 JP2003584060A JP2003584060A JP2005534624A5 JP 2005534624 A5 JP2005534624 A5 JP 2005534624A5 JP 2003584060 A JP2003584060 A JP 2003584060A JP 2003584060 A JP2003584060 A JP 2003584060A JP 2005534624 A5 JP2005534624 A5 JP 2005534624A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- furo
- azabicyclo
- spiro
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- UTNQUMOIHZDNPR-FQEVSTJZSA-N (3r)-5'-(1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1=CC=C2SC(C=3C=C4C[C@]5(C6CCN(CC6)C5)OC4=NC=3)=NC2=C1 UTNQUMOIHZDNPR-FQEVSTJZSA-N 0.000 claims 1
- YLVFFNFPLJAZEC-FQEVSTJZSA-N (3r)-5'-(1,3-benzoxazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1=CC=C2OC(C=3C=C4C[C@]5(C6CCN(CC6)C5)OC4=NC=3)=NC2=C1 YLVFFNFPLJAZEC-FQEVSTJZSA-N 0.000 claims 1
- ZMMGHYIOVFHICY-INIZCTEOSA-N (3r)-5'-(1,3-oxazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C([C@]1(C2CCN(CC2)C1)OC1=NC=2)C1=CC=2C1=NC=CO1 ZMMGHYIOVFHICY-INIZCTEOSA-N 0.000 claims 1
- PGMPAGCXAUEGDP-INIZCTEOSA-N (3r)-5'-(1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C([C@]1(C2CCN(CC2)C1)OC1=NC=2)C1=CC=2C1=NC=CS1 PGMPAGCXAUEGDP-INIZCTEOSA-N 0.000 claims 1
- STWUDQAOEPYQAW-INIZCTEOSA-N (3r)-5'-(1,3-thiazol-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C([C@]1(C2CCN(CC2)C1)OC1=NC=2)C1=CC=2C1=CSC=N1 STWUDQAOEPYQAW-INIZCTEOSA-N 0.000 claims 1
- JNEIQTNYQGYWIF-INIZCTEOSA-N (3r)-5'-(1,3-thiazol-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C([C@]1(C2CCN(CC2)C1)OC1=NC=2)C1=CC=2C1=CN=CS1 JNEIQTNYQGYWIF-INIZCTEOSA-N 0.000 claims 1
- OPNPJEFFAANXTO-KRWDZBQOSA-N (3r)-5'-(2-methyl-1,3-thiazol-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound S1C(C)=NC(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)=C1 OPNPJEFFAANXTO-KRWDZBQOSA-N 0.000 claims 1
- IAADVLIGDRQHCI-KRWDZBQOSA-N (3r)-5'-(2-methyl-1,3-thiazol-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound S1C(C)=NC=C1C1=CN=C(O[C@]2(C3)C4CCN(CC4)C2)C3=C1 IAADVLIGDRQHCI-KRWDZBQOSA-N 0.000 claims 1
- RGLYDBOOHIFTEH-SFHVURJKSA-N (3r)-5'-(3,5-dimethyl-1,2-oxazol-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound CC1=NOC(C)=C1C1=CN=C(O[C@]2(C3)C4CCN(CC4)C2)C3=C1 RGLYDBOOHIFTEH-SFHVURJKSA-N 0.000 claims 1
- RQIXRQFMWVNYQT-INIZCTEOSA-N (3r)-5'-[2-(trifluoromethyl)-1,3-thiazol-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound S1C(C(F)(F)F)=NC(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)=C1 RQIXRQFMWVNYQT-INIZCTEOSA-N 0.000 claims 1
- MFKLMAUXODZWDR-INIZCTEOSA-N (3r)-5'-[2-(trifluoromethyl)-1,3-thiazol-5-yl]spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound S1C(C(F)(F)F)=NC=C1C1=CN=C(O[C@]2(C3)C4CCN(CC4)C2)C3=C1 MFKLMAUXODZWDR-INIZCTEOSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201185A SE0201185D0 (sv) | 2002-04-18 | 2002-04-18 | Heterocyclic compounds |
| SE0203606A SE0203606D0 (sv) | 2002-12-04 | 2002-12-04 | Heterocyclic compounds |
| PCT/SE2003/000615 WO2003087104A1 (en) | 2002-04-18 | 2003-04-15 | Heterocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005534624A JP2005534624A (ja) | 2005-11-17 |
| JP2005534624A5 true JP2005534624A5 (enExample) | 2006-06-01 |
| JP4523775B2 JP4523775B2 (ja) | 2010-08-11 |
Family
ID=29253787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584060A Expired - Fee Related JP4523775B2 (ja) | 2002-04-18 | 2003-04-15 | 複素環化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7417050B2 (enExample) |
| EP (1) | EP1499616B1 (enExample) |
| JP (1) | JP4523775B2 (enExample) |
| KR (1) | KR20040099446A (enExample) |
| CN (1) | CN1325501C (enExample) |
| AT (1) | ATE433981T1 (enExample) |
| AU (1) | AU2003224546B2 (enExample) |
| BR (1) | BR0309345A (enExample) |
| CA (1) | CA2482313A1 (enExample) |
| DE (1) | DE60328010D1 (enExample) |
| ES (1) | ES2326638T3 (enExample) |
| HK (1) | HK1080470B (enExample) |
| IL (1) | IL164511A0 (enExample) |
| MX (1) | MXPA04010190A (enExample) |
| NO (1) | NO20044995L (enExample) |
| NZ (1) | NZ561993A (enExample) |
| WO (1) | WO2003087104A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| EP1432707B1 (en) | 2001-10-02 | 2012-03-28 | Pharmacia & Upjohn Company LLC | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| RS53365B (sr) | 2003-08-01 | 2014-10-31 | Mitsubishi Tanabe Pharma Corporation | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma |
| MXPA06003196A (es) | 2003-09-25 | 2006-06-23 | Astrazeneca Ab | Ligandos. |
| BRPI0415546A (pt) * | 2003-10-21 | 2006-12-26 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |
| US7045530B2 (en) | 2003-12-22 | 2006-05-16 | Abbott Laboratories | Spirocyclic quinuclidinic ether derivatives |
| TW200813067A (en) * | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| NO2200606T3 (enExample) | 2007-09-10 | 2018-03-24 | ||
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| ES2325049B2 (es) * | 2008-02-21 | 2010-03-16 | Universidade De Santiago De Compostela | Deteccion y cuantificacion de iminas ciclicas basada en la union competitiva a receptores nicotinicos de acetilcolina. |
| EP2307389B1 (en) | 2008-06-20 | 2013-01-23 | AstraZeneca AB | Dibenzothiazepine derivative and use thereof |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| PL2488515T3 (pl) | 2009-10-14 | 2017-07-31 | Janssen Pharmaceutica Nv | Sposób wytwarzania związków użytecznych jako inhibitory sglt2 |
| LT2568988T (lt) | 2010-05-11 | 2016-09-12 | Janssen Pharmaceutica, N.V. | Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius |
| CA2799744C (en) | 2010-05-17 | 2020-01-28 | Envivo Pharmaceuticals, Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| KR101913587B1 (ko) | 2011-04-13 | 2018-10-31 | 얀센 파마슈티카 엔.브이. | Sglt2의 억제제로서 유용한 화합물의 제조 방법 |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9585877B2 (en) | 2012-05-08 | 2017-03-07 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| FR2788982B1 (fr) * | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| PT1397366E (pt) | 2001-06-01 | 2007-04-30 | Astrazeneca Ab | Novo ligando para os receptores nicotínicos da acetilcolina úteis em terapia |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
-
2003
- 2003-04-15 NZ NZ561993A patent/NZ561993A/en unknown
- 2003-04-15 AT AT03721209T patent/ATE433981T1/de not_active IP Right Cessation
- 2003-04-15 CA CA002482313A patent/CA2482313A1/en not_active Abandoned
- 2003-04-15 AU AU2003224546A patent/AU2003224546B2/en not_active Ceased
- 2003-04-15 EP EP03721209A patent/EP1499616B1/en not_active Expired - Lifetime
- 2003-04-15 JP JP2003584060A patent/JP4523775B2/ja not_active Expired - Fee Related
- 2003-04-15 DE DE60328010T patent/DE60328010D1/de not_active Expired - Lifetime
- 2003-04-15 BR BR0309345-0A patent/BR0309345A/pt not_active IP Right Cessation
- 2003-04-15 MX MXPA04010190A patent/MXPA04010190A/es active IP Right Grant
- 2003-04-15 ES ES03721209T patent/ES2326638T3/es not_active Expired - Lifetime
- 2003-04-15 WO PCT/SE2003/000615 patent/WO2003087104A1/en not_active Ceased
- 2003-04-15 KR KR10-2004-7016545A patent/KR20040099446A/ko not_active Ceased
- 2003-04-15 CN CNB038139014A patent/CN1325501C/zh not_active Expired - Fee Related
- 2003-04-15 HK HK06100288.5A patent/HK1080470B/zh not_active IP Right Cessation
- 2003-04-15 US US10/511,525 patent/US7417050B2/en not_active Expired - Fee Related
-
2004
- 2004-10-11 IL IL16451104A patent/IL164511A0/xx unknown
- 2004-11-17 NO NO20044995A patent/NO20044995L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005534624A5 (enExample) | ||
| JP2005527588A5 (enExample) | ||
| US12065436B2 (en) | Cardiac sarcomere inhibitors | |
| KR100571161B1 (ko) | 벤조티아졸 유도체 | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| RU2009138600A (ru) | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов | |
| JP2003512374A5 (enExample) | ||
| WO2018057973A4 (en) | Compounds and methods for ido and tdo modulation, and indications therefor | |
| RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
| RU2001122812A (ru) | Новые аралкиламины спирофуропиридинов, полезные в терапии | |
| WO2013006408A1 (en) | Compounds and methods | |
| JP2003513071A5 (enExample) | ||
| CN102918031A (zh) | 放射标记的化合物及其方法 | |
| JP2003511384A5 (enExample) | ||
| RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
| JP2019529445A5 (enExample) | ||
| CN109689042A (zh) | 用于治疗黄斑变性的与恩他卡朋相关的化合物 | |
| JP6466937B2 (ja) | 三環式ピペリジン化合物 | |
| JP2005508969A5 (enExample) | ||
| CN102603734A (zh) | 一种蛋白激酶抑制剂及其应用 | |
| JP2002121153A (ja) | 抑うつ及び不安のための併合療法 | |
| JP2007515479A5 (enExample) | ||
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина | |
| JP2008526818A5 (enExample) | ||
| JP2009538909A5 (enExample) |